LogicBio’s partnering strategy focuses on furthering our ability to deliver the hope of genetic medicine to people impacted by devastating diseases.

We actively seek collaboration and licensing opportunities that allow us to further explore our GeneRide^TM and sAAVy^TM platforms.

If interested in partnering with LogicBio, please contact: partnering@logicbio.com

In April 2021, the Company entered into an Exclusive Research Collaboration, License and Option Agreement with CANbridge Care Pharma Hong Kong Limited (CANbridge), pursuant to which LogicBio granted CANbridge (1) an exclusive worldwide license to certain of the Company’s intellectual property rights, including those relating to adeno-associated virus sL65, the first capsid produced from LogicBio’s sAAVy platform, to develop, manufacture and commercialize gene therapy candidates for the treatment of Fabry and Pompe diseases, (2) an option to obtain an exclusive worldwide license to certain of the Company’s intellectual property rights, including those relating to sL65, to develop and commercialize gene therapy candidates for the treatment of two additional indications, and (3) an exclusive option to obtain an exclusive license to develop and commercialize LogicBio’s lead investigational therapy, LB-001, for the treatment of MMA in China, Taiwan, Hong Kong and Macau.

In April 2021, LogicBio announced a research collaboration with Daiichi Sankyo Company, Limited (Daiichi) for the development of treatments for two indications based on LogicBio’s GeneRide platform. The agreement with Daiichi also granted Daiichi an exclusive, non-binding option to enter into a license agreement with respect to each of the treatments being developed.

In January 2020, LogicBio entered into collaboration with Takeda Pharmaceutical Company Limited (Takeda) to develop LB-301, an investigational therapy leveraging LogicBio’s GeneRide platform, for the treatment of Crigler-Najjar syndrome, a rare pediatric disease.